Serum levels of prolidase and ischemia modified albumin in patients with multiple sclerosis

Abstract

Objectives: Increased levels of free radicals and oxidant molecules and decreased levels of antioxidant molecules have been defined in patients with multiple sclerosis (MS). Ischemia-modified albumin (IMA) levels have been advocated as a biomarker for evaluating the oxidative stress status. The aim of this study was to investigate the relationship between oxidative stress and MS. Materials and methods: We compared serum ischemia modified albumin levels and prolidase activity of 42 patients with MS (30 female, 12 male) and 30 age-matched healthy controls (21 female, 9 male). Results: Ischemia modified albumin levels of MS patients (73,07±26,53 ng/mL) were significantly higher than those of controls (60,18±18,01 ng/mL) (p=0.024). However, there were no significant differences in prolidase levels between patients and healthy controls (p=0.856). Conclusions: Increased ischemia modified albumin levels, supports the role of oxidative stress in patients with multiple sclerosis.

Keywords

• Multiple sclerosis, ischemia modified albumin, prolidase, oxidative stress

Multipl sklerozlu hastalarda serum prolidaz ve iskemi modifiye albümin düzeyleri

Öz

Amaç: Multipl skleroz (MS) hastalarında oksidan moleküller olan serbest radikallerin arttığı ve antioksidan moleküllerin düzeylerinin azaldığı bilinmektedir. İskemik modifiye albüminin oksidatif stresi gösterebilecek biyolojik bir belirteç olduğu savunulmaktadır. Bu çalışmanın amacı MS ve oksidatif stres ilişkisini göstermektir. Gereç ve yöntem: Kırk iki MS hastası (30 kadın, 12 erkek) ve 30 sağlıklı kontrol (21 kadın, 9 erkek) bireyde iskemik modifiye albümin düzeyleri ve prolidaz aktivitesi ölçüldü. Bulgular: İskemik modifiye albümin düzeyleri MS hastalarında (73,07±26,53 ng/mL) kontrol grubuna (60,18±18,01 ng/mL) göre anlamlı düzeyde yüksek bulundu (p=0.024). Hasta ve kontrol grupları arasında prolidaz seviyeleri açısından ise anlamlı fark saptanmadı (p =0.856). Sonuç: İskemik modifiye albümin düzeylerinin artışı multipl skleroz hastalarında oksidatif stresin rolünü destekler.

Anahtar Kelimeler

• Multipl skleroz, iskemik modifiye albümin. Prolidaz, oksidatif stres

Kaynakça

1. Gilgun SY, Melamed E, Offen D. The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J Neurol 2004; 251(3):261-8.
2. Verma P, Bhattacharya SN, Banerjee BD, et al. Oxi dative stress and leukocyte migration inhibition re sponse in cutaneous adverse drug reactions. Indian J Dermatol Venereol Leprol 2012; 78(5):664.
3. Oliveira SR, Kallaur AP, Simao AN, et al. Oxidative stress in multiple sclerosis patients in clinical remis sion: Association with the expanded disability status scale. J Neurol Sci 2012; 321(1-2):49-53.
4. Syburra C, Passi S. Oxidative stress in patients with multiple sclerosis. Ukr Biokhim Zh 1999; 71(3):112-5.
5. Awadallah SM, Atoum MF, Nimer NA, et al. Ischemia modified albumin: an oxidative stress marker in be ta-thalassemia major. Clin Chim Acta 2012; 413(9 10):907-10.
6. Toy H, Camuzcuoglu H, Camuzcuoglu A, et al. De creased serum prolidase activity and increased oxida tive stress in early pregnancy loss. Gynecol Obstet Invest 2010; 69(2):122-7.
7. Uzar E, Tamam Y, Evliyaoglu O, et al. Serum prolidase activity and oxidative status in patients with diabetic neuropathy. Neurol Sci 2012; 33(4):875-80.
8. Sbarouni E, Georgiadou P, Voudris V. Ischemia modi fied albumin changes - review and clinical implica tions. Clin Chem Lab Med. 2011; 49(2):177-84.

9. Cakir M, Karahan SC, Mentese A, et al. Ischemia modified albumin levels in children with chronic liver disease. Gut Liver 2012; 6(1):92-7.
10. Duygu F, Koruk ST, Karsen H, et al. Prolidase and oxidative stress in chronic hepatitis C. J Clin Lab Anal 2012;26(4):232-7.
11. Erbagci AB, Araz M, Erbagci A, et al. Serum prolidase activity as a marker of osteoporosis in type 2 diabetes mellitus. Clin Biochem 2002;35(4):263-8.
12. Gecit I, Aslan M, Gunes M, et al. Serum prolidase activity, oxidative stress, and nitric oxide levels in pa tients with bladder cancer. J Cancer Res Clin Onco 2012;138(5):739-43.
13. Greco A, Minghetti L, Sette G, et al. Cerebrospinal fluid isoprostane shows oxidative stress in patients with multiple sclerosis. Neurology 1999;53(8):1876-9.
14. Karna E, Surazynski A, Palka J. Collagen metabolism disturbances are accompanied by an increase in pro lidase activity in lung carcinoma planoepitheliale. Int J Exp Pathol 2000;81(5):341-7.
15. Brown WR, Thore CR. Perivascular fibrosis in multiple sclerosis lesions. Brain Pathol 2011;21(3):355.
16. Mohan H, Krumbholz M, Sharma R, et al. Extracel lular matrix in multiple sclerosis lesions: Fibrillar col lagens, biglycan and decorin are upregulated and associated with infiltrating immune cells. Brain Pathol 2010;20(5):966-75.
17. Zhong Y, Wang N, Xu H, et al. Ischemia-modified albumin in stable coronary atherosclerotic heart dis ease: clinical diagnosis and risk stratification. Coron Artery Dis 2012. Epub 2012/09/01.
18. Ma SG, Jin Y, Xu W, Hu W, Bai F, Wu XJ. Increased serum levels of ischemia-modified albumin and C-re active protein in type 1 diabetes patients with ketoaci dosis. Endocrine 2012. Epub 2012/03/23.
19. Han K, Jia N, Yang L, et al. Correlation between isch emia-modified albumin and lipid levels in patients with acute cerebrovascular disease. Mol Med. Reports 2012;6(3):621-4.